Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Male » Prostatic Diseases » Prostatic Hyperplasia
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Genital Diseases, Male » Prostatic Diseases » Prostatic Hyperplasia
Description
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. MeSH
Hierarchy View
Phase 4 Indicated Drugs (21)
Phase 2 Indicated Drugs (19)
Phase 1 Indicated Drugs (2)
Organization Involved with Phase 4 Indications (49)
Organization Involved with Phase 3 Indications (54)
Health Ever Bio-Tech Co., Ltd.
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Organization Involved with Phase 2 Indications (29)
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (14)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
